Home » Posts tagged 'ekf diagnostics'
Tag Archives: ekf diagnostics
Finsbury Food Growth Halted
Finsbury Food Group FIF A successfull roll out of vision and values appears to have been the main feature of Finsbury’s second half and once you see management reduced to that level of jargon, you know that something is not quite right. Well revenue for one thing was completely flat, in fact it was so flat that the first and second half revenues were virtually identical – so much for meaningless empty phrases like vision and value. Profit before tax for the 26 weeks to the end of December rose by 5.3% and the interim dividend was increased by 7.5%. The CEO refers to the company’strack record of exceptional growth but offers no explanation as to why that should suddenly have come to a halt in the second half of 2016.
EKF Diagnostics EKF A successful restructuring helped to produce strong organic growth in the year to the end of December, with revenue rising by 28% and gross profits by 24%. EBITDA of £6.1m compared to 2015’s loss of £2.9m
Volution Group FAN is increasing its interim dividend by 12.5% for the half year to 31st January. Revenue grew by 26.1% or 2.3% on a like for like and constant currency basis. Reported profit before tax grew by 10% compaed to the first half of 2016. Further good growth is expected in 2017.
Taptica TAP A strong performance for the year to the end of December saw revenue rise by 66% and gross profit more than double. Adjusted EBITDA more than tripled to $25.7m and an increase in the final dividend means an increase for the year from 0.00784 to $0.1011 cents per share.
Villas & Houses For Sale in Greece; http://www.hiddengreece
Ryanair Beats The Competition
Ryanair Holdings RYA has more than halved its planned UK growth from 12% to 5% because of weaker sterling and slower economic growth. For the half year to 30th September profits rose by 7% on fares down by 10% and unit costs also down by 10%. Basic earnings per share for the half year rose by 15%. Some competitors have been unable to stand the competition and have closed bases and routes. The 18% fall in sterling has reduced full year guidance by 75m Euro.
Hiscox HSX In the 9 months to 30th September material foreign exchange gains helped Hiscox to increase gross written premiums by 20.9%, compared to 14.3% in local currency. All segments put in a strong performance but Hiscox London Market and Hiscox RE continued to find trading conditions difficult and margins are evaporating in some areas.
Keywords Studios KWS Revenues and adjusted profit before tax will be significantly ahead of current market expectations for the year to 31st December, with adjusted profit before tax expected to be not less than 14m. Euro.
Fevertree Drinks FEVR has continued to perform strongly in the second half, particularly in the UK and anticipates that results for the year to 31st December will be materially ahead of current market expectations.
EKF Diagnostics EKF Revenue and adjusted EBITDA will exceed current market expectations for the year to the end of December. Early fourth quarter trading has been materially higher than budget and exceeds the previous revised figures.
Dignity DTY Underlying operating profit fell by 2.9% in the 39 weeks to the end of September, slightly ahead of expectations, as the number of deaths declined by 2.9% at the same time as the company lost market share.
Villas & Houses For Sale In The Greek Islands – visit; http://www.hiddengreece.net
Brammer Scraps Final Dividend
Brammer plc BRAM has already decided it will have to scrap its final dividend after it has been forced to go round with its begging bowl and arrange a rights issue. Third quarter group sales per working day which fell by 2% and a reduced level of supplier support mean that quarter three produced an operating loss and a pre tax profit is not expected for the full year to 31st December. The Nordic countries appear to have been a disaster area with quarterly sales falls of 21%, 13% and 13% over the first nine months. And that is not an end to it. Margins have been impacted and further declines are expected in sales of its more profitable products. A business review will have taken months to reach its conclusions by the time they are announced in November. Presumably that is what passes for urgent action but it is already becoming clear to senior management that what will help to solve the company’s problems will be greater focus and greater clarity and the new CEO appointed in August has been going round talking to people. Well that is very comforting.
If ever the argument that a collapse in sterling is good for industry and commerce was exposed as economic nonsense, Brammer provides proof.
EKF Diagnostics EKF Third quarter trading has turned out to be materially higher than budget and has also exceeded market forecasts. Revenue and adjusted EBITDA for the full year are now expected to exceed current market forecasts.
XP Power Ltd XPP Revenue over the nine months to 30th September has risen by 13% and orders by 19%. At constant currency rates the figures are 5% and 11% respectively. The third quarter saw orders at a record £ 34.2m, almost a 50% rise on 2015’s figures, although this was partly due to some orders being brought forwards from October.
Beachfront Property For Sale In The Greek Islands – visit; http://www.hiddengreece.net
Tobacco Sales Drop Sharply at Bookers
Booker Group BOK has seen tobacco sales drop substantially in the face of the latest set of display restrictions, whilst non tobacco sales have been hit by food price deflation. Like for like tobacco sales for the 12 weeks to the 17th June were down by 7.7% and non tobacco fell by 0.7%. Total group sales rose by 10%. Shareholders will be rewarded with a proposed payment of 3.2p per ordinary share by way of return of capital.
Pure Circle PURE expects a 9% increase in 2016 sales and future orders have increased but apart from that today’s update makes for strange reading. Planned customer launches have been delayed into 2017 and problems with US customs appear to be still ongoing to the extent that they have not been resolved, despite release of the shipments detained in May. The CEO says the business model is robust and he is confident that profitability will improve but then come the warnings that there will be continued volatility in the development of the business and sales growth will be uneven.
Topps Tiles TPT has shown healthy growth during the 13 weeks to the 2nd July with like for like sales up by 6.2% on 2015, although the figures have been skewed slightly by Easter moving about a bit.
easyJet plc EZJ June passenger figures rose by 5.8% and the load factor by 1.44pp but on a rolling 12 month basis the load factor rose only a smidgeon by 0.3pp
EKF Diagnostic Holdings EKF expects that after a difficult 2015, the half year to the end of June will be ahead of both budget and expectations. First half revenue is expected to exceed £16.5m and no impact is expected from Brexit.
Find Villas & Houses For Sale In Greece; http://www.hiddengreece.net
Daily Actions – UK Main & AIM markets 15032016
Daily summary analysis of changes in short term actions from our Daily Recs – AIM & Daily Recs Main markets reports
AIM Market
ST Rec. changed | ||
From | To | |
Basic Resources | ||
GCM Resources | Buy | Neutral |
Goldstone Resources | Neutral | Buy |
Jubilee Platinum | Buy | Neutral |
Metals Exploration | Buy | Neutral |
Paternoster Resources | Buy | Neutral |
Financial Services | ||
ADVFN | Buy | Strong Buy |
EKF Diagnostics Holdings | Neutral | Buy |
Health Care | ||
Advanced Medical Solution Group | Neutral | Sell |
Industrial Good & Services | ||
Accsys Technologies | Neutral | Buy |
Dart Group | Sell | Neutral |
Yolo Leisure & Technology | Buy | Neutral |
Media | ||
Ten Alps | Neutral | Buy |
Oil & Gas – Producers | ||
Baron Oil | Neutral | Buy |
Personal & Household Goods | ||
Concha | Buy | Neutral |
Retail | ||
Stanley Gibbons Group | Buy | Neutral |
Technology | ||
On-Line | Neutral | Buy |
Travel & Leisure | ||
Minoan Group | Neutral | Buy |
Main Market
ST Rec. changed | ||
From | To | |
Insurance | ||
Novae Group | Sell | Neutral |
Leisure & Hotels | ||
Intercontinental Hotels Group | Neutral | Sell |
Life Assurance | ||
Aviva | Sell | Neutral |
RISK WARNING
Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com
The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.
DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.
Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report. The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK. Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth. Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors. No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company. Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise. Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules. Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance. Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW. |
Daily Actions – UK Main & AIM markets 03032016
Daily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London.
AIM Market
ST Rec. changed | ||
From | To | |
Basic Resources | ||
Centamin | Sell | Neutral |
Mariana Resources | Neutral | Buy |
Solgold | Neutral | Buy |
Construction | ||
Michelmersh Brick Holdings | Buy | Neutral |
Financial Services | ||
FastForward Innovations | Buy | Neutral |
Tengri Resources | Buy | Neutral |
Fletcher King | Buy | Neutral |
Impax Asset Management Group | Buy | Neutral |
EKF Diagnostics Holdings | Neutral | Buy |
Food & Beverage | ||
PureCircle | Buy | Neutral |
Health Care | ||
Proteome Sciences | Buy | Neutral |
Industrial Good & Services | ||
APC Technology Group | Buy | Neutral |
Nakama Group | Buy | Neutral |
Hydro International | Sell | Neutral |
The Kellan Group | Buy | Neutral |
Petards Group | Buy | Neutral |
Oil & Gas – Explorers | ||
Chariot Oil & Gas | Buy | Neutral |
Xcite Energy | Buy | Neutral |
Oil & Gas – Producers | ||
Northern Petroleum | Buy | Neutral |
President Petroleum | Buy | Neutral |
Technology | ||
1Spatial | Buy | Neutral |
Indigovision Group | Buy | Neutral |
Simigon | Buy | Neutral |
Telecommunications | ||
MXC Capital | Buy | Neutral |
Main Market
ST Rec. changed | ||
From | To | |
Banks | ||
Barclays | Buy | Neutral |
Engineering & Machinery | ||
Halma | Sell | Neutral |
Food Producers & Processors | ||
Associated British Foods | Sell | Neutral |
General Retail | ||
Darty | Neutral | Sell |
Media & Entertainment | ||
Photo-Me International | Sell | Neutral |
UBM | Sell | Neutral |
WPP | Sell | Neutral |
Support Services | ||
British Polythene Industries | Neutral | Sell |
RISK WARNING
Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com
The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.
DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK.
Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth. Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors. No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company. Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise. Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules. Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance. Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW. |